Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Monk

Showing results (301-310 of 738) with videos related to

Pageof 74
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 14, 2000
Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervixW A Peters, P Y Liu, R J Barrett, et al.
Gynecologic Oncology|December 11, 2012
Patient reported outcomes of a randomized, placebo-controlled trial of bevacizumab in the front-line treatment of ovarian cancer: a Gynecologic Oncology Group StudyBradley J Monk, Helen Q Huang, Robert A Burger, et al.
European Journal of Cancer (Oxford, England : 1990)|March 21, 2024
Paclitaxel therapeutic drug monitoring - International association of therapeutic drug monitoring and clinical toxicology recommendationsDaniel L Hertz, Markus Joerger, Yung-Jue Bang, et al.
Gynecologic Oncology|July 7, 2012
Patient-reported outcomes in relapsed ovarian cancer: results from a randomized Phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD aloneCarolyn N Krasner, Andres Poveda, Thomas J Herzog, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|September 24, 2015
Expression Patterns of the Wnt Pathway Inhibitors Dickkopf3 and Secreted Frizzled-Related Proteins 1 and 4 in Endometrial Endometrioid Adenocarcinoma: An NRG Oncology/Gynecologic Oncology Group StudyRamez N Eskander, Shamshad Ali, Thanh Dellinger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 5, 2023
Concurrent Chemotherapy and Pelvic Radiation Therapy Compared With Pelvic Radiation Therapy Alone as Adjuvant Therapy After Radical Surgery in High-Risk Early-Stage Cancer of the CervixWilliam A Peters, P Y Liu, Rolland J Barrett, et al.
Gynecologic Oncology|June 21, 2018
A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254)John K Chan, William Brady, Bradley J Monk, et al.
Cancer|March 10, 2001
Primary invasive carcinoma of the vagina: treatment with interstitial brachytherapyK S Tewari, F Cappuccini, A A Puthawala, et al.
Gynecologic Oncology|July 22, 2017
A phase II evaluation of brivanib in the treatment of persistent or recurrent carcinoma of the cervix: An NRG Oncology/Gynecologic Oncology Group studyJohn K Chan, Wei Deng, Robert V Higgins, et al.
Gynecologic Oncology|February 18, 1999
Phase II trial of vinorelbine in recurrent and progressive epithelial ovarian cancerR A Burger, P J DiSaia, J A Roberts, et al.
Pageof 74

Showing results (301-310 of 738) with videos related to

Sort By:
Pageof 74
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 14, 2000
Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervixW A Peters, P Y Liu, R J Barrett, et al.
Gynecologic Oncology|December 11, 2012
Patient reported outcomes of a randomized, placebo-controlled trial of bevacizumab in the front-line treatment of ovarian cancer: a Gynecologic Oncology Group StudyBradley J Monk, Helen Q Huang, Robert A Burger, et al.
European Journal of Cancer (Oxford, England : 1990)|March 21, 2024
Paclitaxel therapeutic drug monitoring - International association of therapeutic drug monitoring and clinical toxicology recommendationsDaniel L Hertz, Markus Joerger, Yung-Jue Bang, et al.
Gynecologic Oncology|July 7, 2012
Patient-reported outcomes in relapsed ovarian cancer: results from a randomized Phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD aloneCarolyn N Krasner, Andres Poveda, Thomas J Herzog, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|September 24, 2015
Expression Patterns of the Wnt Pathway Inhibitors Dickkopf3 and Secreted Frizzled-Related Proteins 1 and 4 in Endometrial Endometrioid Adenocarcinoma: An NRG Oncology/Gynecologic Oncology Group StudyRamez N Eskander, Shamshad Ali, Thanh Dellinger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 5, 2023
Concurrent Chemotherapy and Pelvic Radiation Therapy Compared With Pelvic Radiation Therapy Alone as Adjuvant Therapy After Radical Surgery in High-Risk Early-Stage Cancer of the CervixWilliam A Peters, P Y Liu, Rolland J Barrett, et al.
Gynecologic Oncology|June 21, 2018
A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254)John K Chan, William Brady, Bradley J Monk, et al.
Cancer|March 10, 2001
Primary invasive carcinoma of the vagina: treatment with interstitial brachytherapyK S Tewari, F Cappuccini, A A Puthawala, et al.
Gynecologic Oncology|July 22, 2017
A phase II evaluation of brivanib in the treatment of persistent or recurrent carcinoma of the cervix: An NRG Oncology/Gynecologic Oncology Group studyJohn K Chan, Wei Deng, Robert V Higgins, et al.
Gynecologic Oncology|February 18, 1999
Phase II trial of vinorelbine in recurrent and progressive epithelial ovarian cancerR A Burger, P J DiSaia, J A Roberts, et al.
Pageof 74